After Nearly Dying, Doctor Finds Rare Disease Cure on Pharmacy Shelf—Now Uses AI to Uncover Hidden Cures Everywhere

When Dr. David Fajgenbaum stared at the ceiling of his hospital bed during a life-threatening flare of idiopathic multicentric Castleman’s disease, he never imagined the answer would be sitting on a shelf at his local pharmacy. His personal journey from patient to pioneer has become a beacon for how artificial intelligence can uncover hidden treatments for rare diseases—a story that resonates deeply in communities across America where access to specialized care remains a challenge. In cities like Philadelphia, where world-class medical institutions sit alongside neighborhoods grappling with healthcare disparities, the implications of AI-driven drug repurposing are particularly profound, offering a bridge between cutting-edge science and everyday accessibility.

The core breakthrough came when researchers at the Perelman School of Medicine at the University of Pennsylvania used machine learning to analyze over 4,000 existing medications. Their AI system identified adalimumab—a monoclonal antibody already FDA-approved for conditions like rheumatoid arthritis and Crohn’s disease—as the top-predicted treatment for iMCD. This wasn’t theoretical; when administered to a patient who had been set to enter hospice care, the drug induced remission. What made this approach revolutionary was its efficiency: instead of waiting years for new drug development, the team looked at medications already proven safe, whose mechanisms might align with poorly understood diseases. As Dr. Fajgenbaum explained in interviews with Every Cure, the organization he co-founded, there’s a moral imperative to find treatments that may already exist in local pharmacies rather than forcing patients to wait for novel therapies that may never arrive.

This philosophy gains urgency when considering the scale of unmet medical need. Of approximately 18,000 recognized diseases, only about 4,000 have FDA-approved treatments, leaving over 300 million people worldwide without adequate options. For rare diseases specifically, the financial incentives for pharmaceutical companies to develop new drugs are often insufficient, creating what experts call the “orphan drug gap.” AI repurposing flips this equation by leveraging existing safety data—dramatically reducing both development time and cost. When Every Cure’s AI analyzes global biomedical knowledge, it’s not just matching drugs to diseases; it’s revealing patterns in molecular biology that might otherwise remain hidden, like the elevated tumor necrosis factor signaling observed in severe iMCD cases that pointed to adalimumab’s mechanism of action.

In Philadelphia, this research has tangible connections. The Perelman School of Medicine, consistently ranked among the nation’s top medical schools, served as the epicenter for the iMCD study. Nearby, the Children’s Hospital of Philadelphia (CHOP) has its own rare disease initiatives that could benefit from similar AI approaches. Even further afield but still within the region’s medical ecosystem, institutions like Thomas Jefferson University Hospital and Temple University Health System contribute to the city’s reputation as a healthcare innovation hub. What’s particularly relevant for Philadelphians is how this work intersects with local efforts to address health equity—in neighborhoods where access to specialists is limited, knowing that a potential treatment might be available at a corner pharmacy could be transformative.

The socioeconomic ripple effects extend beyond individual patients. When effective treatments are found through repurposing, healthcare systems save millions that would otherwise be spent on experimental therapies or prolonged hospital stays. For a city like Philadelphia, which faces significant Medicaid enrollment and struggles with healthcare costs in safety-net hospitals, these efficiencies matter. As AI tools become more accessible, there’s potential for community health centers and local physicians to participate in the discovery process—not just as prescribers but as contributors to the data ecosystems that power these algorithms. This democratization of medical discovery could help ensure that breakthroughs aren’t confined to academic medical centers but spread through the very communities they aim to serve.

Given my background in analyzing healthcare innovation trends, if this AI-driven repurposing movement impacts you in the Philadelphia area, here are three types of local professionals you should seek:

First, look for translational medicine specialists who work at the intersection of laboratory research and clinical application. These professionals—often found at academic medical centers like Penn Medicine or Temple—understand how to take computational findings and design real-world trials. When evaluating them, prioritize those with published work in drug repurposing or experience collaborating with data science teams, as they’ll be best positioned to assess whether an AI-identified candidate makes biological sense for your specific condition.

Second, consider clinical pharmacists with genomics expertise, increasingly vital in personalized medicine approaches. In Philadelphia, many hospital-based pharmacists at institutions like CHOP or Jefferson now have advanced training in pharmacogenomics—they can help interpret how your genetic profile might affect response to a repurposed drug and monitor for interactions with existing medications. Seek those who participate in multidisciplinary tumor boards or rare disease clinics, as this indicates they’re accustomed to complex, nuanced cases where standard protocols don’t apply.

Third, engage health data liaisons at community organizations or public health departments. These aren’t always traditional medical roles but rather specialists who bridge clinical settings with data resources—consider professionals at the Philadelphia Department of Public Health or nonprofits like Health Federation of Philadelphia who understand how to access and interpret biomedical databases. When consulting them, request about their experience with AI tool validation and their connections to research networks, as they can help you navigate whether local participation in repurposing studies is feasible and safe.

Ready to find trusted professionals? Browse our complete directory of top-rated experts in the Philadelphia area today.